Elite Pharmaceuticals (OTCMKTS:ELTP) Issues Quarterly Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) released its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, Zacks reports. Elite Pharmaceuticals had a positive return on equity of 15.55% and a negative net margin of 8.98%.

Elite Pharmaceuticals Stock Up 6.5 %

OTCMKTS:ELTP traded up $0.03 during midday trading on Thursday, hitting $0.55. 1,739,250 shares of the company were exchanged, compared to its average volume of 798,234. Elite Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $0.75. The company has a market capitalization of $585.25 million, a PE ratio of -54.78 and a beta of 0.27. The company has a current ratio of 3.52, a quick ratio of 2.42 and a debt-to-equity ratio of 0.10. The company has a fifty day simple moving average of $0.52 and a 200 day simple moving average of $0.44.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.